BEVERLY, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, provides a brief summary of preliminary data collected during a clinical validation study conducted at two of the top five veterinary universities in the nation.1
LexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infections
Globe Newswire -
Wed Jul 27, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Apple%20Inc%20phone%20and%20data-by%20Anderson%20Reis%20via%20Shutterstock.jpg)
/Unitedhealth%20Group%20Inc%20HQ%20photo-by%20jetcityimage%20via%20iStock.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
